Molecular screening to select therapy for advanced cancer?
I F Tannock  J A Hickman
Annals of Oncology, Volume 30, Issue 5, May 2019, Pages 661–663, https://doi.org/10.1093/annonc/mdz088
Published: 13 March 2019
Cite
Permissions Icon Permissions
 Share 
Issue Section: Editorials
In this issue of Annals of Oncology, Trédan et al. [1] describe the results of the ProfiLER trial, in which 2579 adult and paediatric patients with previously treated metastatic cancer underwent molecular profiling. Next-generation sequencing (NGS) with two panels was used to sequence 59 or 69 genes, as well as microarray-based comparative genomic hybridization, to define genetic changes that might be targeted for effective therapy. Oncologists in four academic institutions in and around Lyon, France, managed the patients; the authors are to be congratulated on overcoming the logistics of undertaking such a large multi-institution trial. The primary aim of the...

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)